<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02714062</url>
  </required_header>
  <id_info>
    <org_study_id>OB-402</org_study_id>
    <nct_id>NCT02714062</nct_id>
  </id_info>
  <brief_title>A Pharmacokinetic Study Comparing VI-0521 With Placebo in Obese Adolescents</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Pharmacokinetic and Pharmacodynamic Study of VI-0521 in Obese Adolescents</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VIVUS, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VIVUS, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to describe the pharmacokinetic profiles of VI-0521 in
      obese adolescents.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 2016</start_date>
  <completion_date type="Actual">November 2016</completion_date>
  <primary_completion_date type="Actual">October 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Apparent Clearance (CL/F) of Phentermine and Topiramate</measure>
    <time_frame>On Days 14, 28, 42, and 56</time_frame>
    <description>A Bayesian analysis was performed to derive posterior Bayes individual pharmacokinetic (PK) parameters.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Volume of Distribution (Vc/F) of Phentermine and Topiramate</measure>
    <time_frame>On Days 14, 28, 42, and 56</time_frame>
    <description>A Bayesian analysis was performed to derive posterior Bayes individual PK parameters.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Curve (AUC) of Phentermine</measure>
    <time_frame>On Days 14, 28, 42, and 56</time_frame>
    <description>A Bayesian analysis was performed to derive posterior Bayes individual PK parameters. AUC from time 0 to 24 hours under steady-state.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Concentration (Cmax) of Phentermine</measure>
    <time_frame>On Days 14, 28, 42, and 56</time_frame>
    <description>A Bayesian analysis was performed to derive posterior Bayes individual PK parameters.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Curve (AUC) of Topiramate</measure>
    <time_frame>On Days 14, 28, 42, and 56</time_frame>
    <description>A Bayesian analysis was performed to derive posterior Bayes individual PK parameters. AUC from time 0 to 24 hours under steady-state.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Concentration (Cmax) of Topiramate</measure>
    <time_frame>On Days 14, 28, 42, and 56</time_frame>
    <description>A Bayesian analysis was performed to derive posterior Bayes individual PK parameters.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Weight Loss</measure>
    <time_frame>56 days</time_frame>
    <description>Mean percent weight change from baseline to Day 56</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Waist Circumference</measure>
    <time_frame>56 days</time_frame>
    <description>Mean change in waist circumference from baseline to Day 56</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Blood Pressure</measure>
    <time_frame>56 days</time_frame>
    <description>Mean change in blood pressure from baseline to Day 56</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in OGTT of Fasting and 2-hour Glucose</measure>
    <time_frame>56 days</time_frame>
    <description>Mean changes in glycemic parameters (OGTT of fasting and 2-hour glucose) from baseline to Day 56</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Lipid Parameters</measure>
    <time_frame>56 days</time_frame>
    <description>Mean percent changes in lipid parameters, including total cholesterol, LDL-C, HDL-C and triglycerides (TG) from baseline to Day 56</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Visual Analog Scale (VAS) Hunger Scores</measure>
    <time_frame>56 days</time_frame>
    <description>Mean change in visual analog scale (VAS) hunger scores from baseline to Day 56. VAS hunger score is measured using a 10.0 cm horizontal line. The left end of this line is defined by word descriptors &quot;not at all hungry&quot; and corresponds to a VAS hunger score of 0.0. The right end of this line is defined by word descriptors &quot;extremely hungry all the time&quot; and corresponds to a VAS hunger score of 10.0. Subjects were asked &quot;Please mark with a perpendicular line on the scale how hungry you were overall during the past week:&quot; to best describes their overall level of hunger during the past week. Research staff measure the distance between the &quot;0.0 = not at all hungry&quot; anchor and the mark made by the subject (length to the nearest tenth of a centimeter) to score the measure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Visual Analog Scale (VAS) Satiety Scores</measure>
    <time_frame>56 days</time_frame>
    <description>Mean change in visual analog scale (VAS) satiety scores from baseline to Day 56. VAS satiety score is measured using a 10.0 cm horizontal line. The left end of this line is defined by word descriptors &quot;very satisfied&quot; and corresponds to a VAS satiety score of 0.0. The right end of this line is defined by word descriptors &quot;not all at satisfied&quot; and corresponds to a VAS satiety score of 10.0. Subjects were asked &quot;Please mark with a perpendicular line on the scale how satisfied you were after eating during the past week:&quot; to evaluate how satisfied subjects are after eating during the past week. Research staff measure the distance between the &quot;0.0 = very satisfied&quot; anchor and the mark made by the subject (length to the nearest tenth of a centimeter) to score the measure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HOMA-IR</measure>
    <time_frame>56 days</time_frame>
    <description>Mean changes in glycemic parameters (HOMA-IR) from baseline to Day 56</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Whole Body Insulin Sensitivity Index (WBISI) (Matsuda)</measure>
    <time_frame>56 days</time_frame>
    <description>Mean changes in glycemic parameters [Whole Body Insulin Sensitivity Index (WBISI) (Matsuda)] from baseline to Day 56. The Oral Glucose Tolerance Test (OGTT) were performed at Baseline and Day 56 using 75 g oral glucose load; blood samples were obtained at baseline and at 2 hours post glucose load for evaluation of both glucose and insulin levels. Insulin Sensitivity was measured by obtaining glucose and insulin levels in a fasting state and at 2 hours after administration of oral glucose load. Matsuda index = 10,000/SQRT [glucose concentration (mg/dL) (fasting)*insulin concentration (uIU/mL) (fasting)*glucose concentration (mg/dL) (2 hours after glucose load)*insulin concentration (uIU/mL) (2 hours after glucose load)], with higher numbers indicating better insulin sensitivity.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Pediatric Obesity</condition>
  <condition>Childhood Obesity</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Days 1-56: Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VI-0521 Mid Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Days 1-14: VI-0521 (Phentermine/Topiramate 3.75 mg/23 mg)
Days 15-56: VI-0521 (Phentermine/Topiramate 7.5 mg/46 mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VI-0521 Top Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Days 1-14: VI-0521 (Phentermine/Topiramate 3.75 mg/23 mg)
Days 15-28: VI-0521 (Phentermine/Topiramate 7.5 mg/46 mg)
Days 29-42: VI-0521 (Phentermine/Topiramate 11.25 mg/69 mg)
Days 43-56: VI-0521 (Phentermine/Topiramate 15 mg/92 mg)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>po once daily</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Sugar Pill</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VI-0521 Mid Dose</intervention_name>
    <description>po once daily</description>
    <arm_group_label>VI-0521 Mid Dose</arm_group_label>
    <other_name>Phentermine/Topiramate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VI-0521 Top Dose</intervention_name>
    <description>po once daily</description>
    <arm_group_label>VI-0521 Top Dose</arm_group_label>
    <other_name>Phentermine/Topiramate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provide written informed consent;

          -  Provide written assent (of study subject);

          -  Adolescent ≥12 and &lt;18 years of age;

          -  Have a BMI ≥ the 95th percentile of BMI for age and gender;

          -  Female subjects must be using adequate contraception;

          -  Willing and able to comply with all study requirements

        Exclusion Criteria:

          -  Condition or disease interfering with metabolism;

          -  Any medical treatment with insulin;

          -  Hyperthyroidism, or clinically significant hypothyroidism;

          -  Any history of bipolar disorder or psychosis, major depressive disorder, or history of
             suicidal behavior or ideation, or any use of antidepressant medications;

          -  Use of chronic systemic glucocorticoid or steroid therapy;

          -  History of any eating disorders;

          -  Any history of laxative abuse;

          -  Prior bariatric surgery;

          -  Any history of nephrolithiasis;

          -  Any history of epilepsy, or treatment with anti-seizure medications;

          -  Positive urine drug screen;

          -  Current smoker or smoking cessation within the previous 3 months of screening;

          -  Obesity of a known genetic or endocrine origin;

          -  Treatment with any over-the-counter or prescription weight loss drug, or
             attention-deficit/hyperactivity disorder (ADHD);

          -  Allergy or hypersensitivity to phentermine or topiramate or history of anaphylaxis to
             any drug;

          -  Use of any investigational medication or device for any indication or participation in
             a clinical study within 30 days prior to screening; or

          -  Any medical or surgical condition which would impair the ability of the subject to
             complete the study, compromise the quality of study data, or pose an unacceptable risk
             to the safety of the subject.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel Hsia, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pennington Biomedical Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70808</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Marrero</city>
        <state>Louisiana</state>
        <zip>70072</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 8, 2016</study_first_submitted>
  <study_first_submitted_qc>March 15, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 21, 2016</study_first_posted>
  <results_first_submitted>October 24, 2017</results_first_submitted>
  <results_first_submitted_qc>January 16, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">February 5, 2018</results_first_posted>
  <last_update_submitted>February 7, 2018</last_update_submitted>
  <last_update_submitted_qc>February 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Adolescent Obesity</keyword>
  <keyword>Childhood Obesity</keyword>
  <keyword>Qsymia</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>VI-0521</keyword>
  <keyword>Phentermine</keyword>
  <keyword>Topiramate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Pediatric Obesity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Topiramate</mesh_term>
    <mesh_term>Phentermine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Days 1-56: Placebo</description>
        </group>
        <group group_id="P2">
          <title>VI-0521 Mid Dose</title>
          <description>Days 1-14: VI-0521 (Phentermine/Topiramate 3.75 mg/23 mg)
Days 15-56: VI-0521 (Phentermine/Topiramate 7.5 mg/46 mg)</description>
        </group>
        <group group_id="P3">
          <title>VI-0521 Top Dose</title>
          <description>Days 1-14: VI-0521 (Phentermine/Topiramate 3.75 mg/23 mg)
Days 15-28: VI-0521 (Phentermine/Topiramate 7.5 mg/46 mg)
Days 29-42: VI-0521 (Phentermine/Topiramate 11.25 mg/69 mg)
Days 43-56: VI-0521 (Phentermine/Topiramate 15 mg/92 mg)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Days 1-56: Placebo</description>
        </group>
        <group group_id="B2">
          <title>VI-0521 Mid Dose</title>
          <description>Days 1-14: VI-0521 (Phentermine/Topiramate 3.75 mg/23 mg)
Days 15-56: VI-0521 (Phentermine/Topiramate 7.5 mg/46 mg)</description>
        </group>
        <group group_id="B3">
          <title>VI-0521 Top Dose</title>
          <description>Days 1-14: VI-0521 (Phentermine/Topiramate 3.75 mg/23 mg)
Days 15-28: VI-0521 (Phentermine/Topiramate 7.5 mg/46 mg)
Days 29-42: VI-0521 (Phentermine/Topiramate 11.25 mg/69 mg)
Days 43-56: VI-0521 (Phentermine/Topiramate 15 mg/92 mg)</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
            <count group_id="B2" value="15"/>
            <count group_id="B3" value="13"/>
            <count group_id="B4" value="42"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14.1" spread="1.56"/>
                    <measurement group_id="B2" value="14.4" spread="1.30"/>
                    <measurement group_id="B3" value="14.3" spread="1.55"/>
                    <measurement group_id="B4" value="14.3" spread="1.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Apparent Clearance (CL/F) of Phentermine and Topiramate</title>
        <description>A Bayesian analysis was performed to derive posterior Bayes individual pharmacokinetic (PK) parameters.</description>
        <time_frame>On Days 14, 28, 42, and 56</time_frame>
        <population>PK samples were not collected for some patients due to withdrawal, or missed visits, etc. As a result, number analyzed for some visits is less than overall number analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>VI-0521 Mid Dose</title>
            <description>Days 1-14: VI-0521 (Phentermine/Topiramate 3.75 mg/23 mg)
Days 15-56: VI-0521 (Phentermine/Topiramate 7.5 mg/46 mg)</description>
          </group>
          <group group_id="O2">
            <title>VI-0521 Top Dose</title>
            <description>Days 1-14: VI-0521 (Phentermine/Topiramate 3.75 mg/23 mg)
Days 15-28: VI-0521 (Phentermine/Topiramate 7.5 mg/46 mg)
Days 29-42: VI-0521 (Phentermine/Topiramate 11.25 mg/69 mg)
Days 43-56: VI-0521 (Phentermine/Topiramate 15 mg/92 mg)</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Clearance (CL/F) of Phentermine and Topiramate</title>
          <description>A Bayesian analysis was performed to derive posterior Bayes individual pharmacokinetic (PK) parameters.</description>
          <population>PK samples were not collected for some patients due to withdrawal, or missed visits, etc. As a result, number analyzed for some visits is less than overall number analyzed.</population>
          <units>L/h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 14 (Phentermine)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.33" spread="1.63"/>
                    <measurement group_id="O2" value="7.04" spread="2.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28 (Phentermine)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.33" spread="1.63"/>
                    <measurement group_id="O2" value="7.18" spread="2.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 42 (Phentermine)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.82" spread="1.69"/>
                    <measurement group_id="O2" value="6.49" spread="2.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 56 (Phentermine)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.82" spread="1.69"/>
                    <measurement group_id="O2" value="6.67" spread="2.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14 (Topiramate)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.32" spread="0.333"/>
                    <measurement group_id="O2" value="1.25" spread="0.307"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28 (Topiramate)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.32" spread="0.333"/>
                    <measurement group_id="O2" value="1.27" spread="0.300"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 42 (Topiramate)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.25" spread="0.291"/>
                    <measurement group_id="O2" value="1.20" spread="0.257"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 56 (Topiramate)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.25" spread="0.291"/>
                    <measurement group_id="O2" value="1.18" spread="0.265"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Apparent Volume of Distribution (Vc/F) of Phentermine and Topiramate</title>
        <description>A Bayesian analysis was performed to derive posterior Bayes individual PK parameters.</description>
        <time_frame>On Days 14, 28, 42, and 56</time_frame>
        <population>PK samples were not collected for some patients due to withdrawal, or missed visits, etc. As a result, number analyzed for some visits is less than overall number analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>VI-0521 Mid Dose</title>
            <description>Days 1-14: VI-0521 (Phentermine/Topiramate 3.75 mg/23 mg)
Days 15-56: VI-0521 (Phentermine/Topiramate 7.5 mg/46 mg)</description>
          </group>
          <group group_id="O2">
            <title>VI-0521 Top Dose</title>
            <description>Days 1-14: VI-0521 (Phentermine/Topiramate 3.75 mg/23 mg)
Days 15-28: VI-0521 (Phentermine/Topiramate 7.5 mg/46 mg)
Days 29-42: VI-0521 (Phentermine/Topiramate 11.25 mg/69 mg)
Days 43-56: VI-0521 (Phentermine/Topiramate 15 mg/92 mg)</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Volume of Distribution (Vc/F) of Phentermine and Topiramate</title>
          <description>A Bayesian analysis was performed to derive posterior Bayes individual PK parameters.</description>
          <population>PK samples were not collected for some patients due to withdrawal, or missed visits, etc. As a result, number analyzed for some visits is less than overall number analyzed.</population>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 14 (Phentermine)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="289" spread="80.4"/>
                    <measurement group_id="O2" value="289" spread="70.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28 (Phentermine)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="287" spread="79.8"/>
                    <measurement group_id="O2" value="291" spread="69.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 42 (Phentermine)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="284" spread="79.3"/>
                    <measurement group_id="O2" value="298" spread="62.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 56 (Phentermine)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="281" spread="78.8"/>
                    <measurement group_id="O2" value="299" spread="64.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14 (Topiramate)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.8" spread="17.7"/>
                    <measurement group_id="O2" value="46.1" spread="13.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28 (Topiramate)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.2" spread="17.5"/>
                    <measurement group_id="O2" value="46.6" spread="13.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 42 (Topiramate)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.7" spread="17.3"/>
                    <measurement group_id="O2" value="48.2" spread="11.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 56 (Topiramate)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.2" spread="17.2"/>
                    <measurement group_id="O2" value="47.5" spread="12.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Curve (AUC) of Phentermine</title>
        <description>A Bayesian analysis was performed to derive posterior Bayes individual PK parameters. AUC from time 0 to 24 hours under steady-state.</description>
        <time_frame>On Days 14, 28, 42, and 56</time_frame>
        <population>PK samples were not collected for some patients due to withdrawal, or missed visits, etc. As a result, number analyzed for some visits is less than overall number analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>VI-0521 Mid Dose</title>
            <description>Days 1-14: VI-0521 (Phentermine/Topiramate 3.75 mg/23 mg)
Days 15-56: VI-0521 (Phentermine/Topiramate 7.5 mg/46 mg)</description>
          </group>
          <group group_id="O2">
            <title>VI-0521 Top Dose</title>
            <description>Days 1-14: VI-0521 (Phentermine/Topiramate 3.75 mg/23 mg)
Days 15-28: VI-0521 (Phentermine/Topiramate 7.5 mg/46 mg)
Days 29-42: VI-0521 (Phentermine/Topiramate 11.25 mg/69 mg)
Days 43-56: VI-0521 (Phentermine/Topiramate 15 mg/92 mg)</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve (AUC) of Phentermine</title>
          <description>A Bayesian analysis was performed to derive posterior Bayes individual PK parameters. AUC from time 0 to 24 hours under steady-state.</description>
          <population>PK samples were not collected for some patients due to withdrawal, or missed visits, etc. As a result, number analyzed for some visits is less than overall number analyzed.</population>
          <units>ng•h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 14 (Phentermine)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="533" spread="109"/>
                    <measurement group_id="O2" value="600" spread="205"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28 (Phentermine)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1066" spread="218"/>
                    <measurement group_id="O2" value="1171" spread="403"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 42 (Phentermine)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1154" spread="240"/>
                    <measurement group_id="O2" value="1902" spread="576"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 56 (Phentermine)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1154" spread="240"/>
                    <measurement group_id="O2" value="2469" spread="775"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Concentration (Cmax) of Phentermine</title>
        <description>A Bayesian analysis was performed to derive posterior Bayes individual PK parameters.</description>
        <time_frame>On Days 14, 28, 42, and 56</time_frame>
        <population>PK samples were not collected for some patients due to withdrawal, or missed visits, etc. As a result, number analyzed for some visits is less than overall number analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>VI-0521 Mid Dose</title>
            <description>Days 1-14: VI-0521 (Phentermine/Topiramate 3.75 mg/23 mg)
Days 15-56: VI-0521 (Phentermine/Topiramate 7.5 mg/46 mg)</description>
          </group>
          <group group_id="O2">
            <title>VI-0521 Top Dose</title>
            <description>Days 1-14: VI-0521 (Phentermine/Topiramate 3.75 mg/23 mg)
Days 15-28: VI-0521 (Phentermine/Topiramate 7.5 mg/46 mg)
Days 29-42: VI-0521 (Phentermine/Topiramate 11.25 mg/69 mg)
Days 43-56: VI-0521 (Phentermine/Topiramate 15 mg/92 mg)</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Concentration (Cmax) of Phentermine</title>
          <description>A Bayesian analysis was performed to derive posterior Bayes individual PK parameters.</description>
          <population>PK samples were not collected for some patients due to withdrawal, or missed visits, etc. As a result, number analyzed for some visits is less than overall number analyzed.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 14 (Phentermine)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.6" spread="5.34"/>
                    <measurement group_id="O2" value="30.3" spread="9.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28 (Phentermine)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.3" spread="10.7"/>
                    <measurement group_id="O2" value="59.3" spread="19.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 42 (Phentermine)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.0" spread="11.6"/>
                    <measurement group_id="O2" value="94.2" spread="25.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 56 (Phentermine)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.1" spread="11.6"/>
                    <measurement group_id="O2" value="123" spread="34.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Weight Loss</title>
        <description>Mean percent weight change from baseline to Day 56</description>
        <time_frame>56 days</time_frame>
        <population>The number of subjects with values at both time points (Baseline and Day 56)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Days 1-56: Placebo</description>
          </group>
          <group group_id="O2">
            <title>VI-0521 Mid Dose</title>
            <description>Days 1-14: VI-0521 (Phentermine/Topiramate 3.75 mg/23 mg)
Days 15-56: VI-0521 (Phentermine/Topiramate 7.5 mg/46 mg)</description>
          </group>
          <group group_id="O3">
            <title>VI-0521 Top Dose</title>
            <description>Days 1-14: VI-0521 (Phentermine/Topiramate 3.75 mg/23 mg)
Days 15-28: VI-0521 (Phentermine/Topiramate 7.5 mg/46 mg)
Days 29-42: VI-0521 (Phentermine/Topiramate 11.25 mg/69 mg)
Days 43-56: VI-0521 (Phentermine/Topiramate 15 mg/92 mg)</description>
          </group>
        </group_list>
        <measure>
          <title>Weight Loss</title>
          <description>Mean percent weight change from baseline to Day 56</description>
          <population>The number of subjects with values at both time points (Baseline and Day 56)</population>
          <units>Percent weight change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.14" spread="2.810"/>
                    <measurement group_id="O2" value="-3.77" spread="2.446"/>
                    <measurement group_id="O3" value="-4.99" spread="3.410"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Waist Circumference</title>
        <description>Mean change in waist circumference from baseline to Day 56</description>
        <time_frame>56 days</time_frame>
        <population>The number of subjects with values at both time points (Baseline and Day 56)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Days 1-56: Placebo</description>
          </group>
          <group group_id="O2">
            <title>VI-0521 Mid Dose</title>
            <description>Days 1-14: VI-0521 (Phentermine/Topiramate 3.75 mg/23 mg)
Days 15-56: VI-0521 (Phentermine/Topiramate 7.5 mg/46 mg)</description>
          </group>
          <group group_id="O3">
            <title>VI-0521 Top Dose</title>
            <description>Days 1-14: VI-0521 (Phentermine/Topiramate 3.75 mg/23 mg)
Days 15-28: VI-0521 (Phentermine/Topiramate 7.5 mg/46 mg)
Days 29-42: VI-0521 (Phentermine/Topiramate 11.25 mg/69 mg)
Days 43-56: VI-0521 (Phentermine/Topiramate 15 mg/92 mg)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Waist Circumference</title>
          <description>Mean change in waist circumference from baseline to Day 56</description>
          <population>The number of subjects with values at both time points (Baseline and Day 56)</population>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="4.17"/>
                    <measurement group_id="O2" value="-2.6" spread="5.63"/>
                    <measurement group_id="O3" value="-4.8" spread="4.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Blood Pressure</title>
        <description>Mean change in blood pressure from baseline to Day 56</description>
        <time_frame>56 days</time_frame>
        <population>The number of subjects with values at both time points (Baseline and Day 56)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Days 1-56: Placebo</description>
          </group>
          <group group_id="O2">
            <title>VI-0521 Mid Dose</title>
            <description>Days 1-14: VI-0521 (Phentermine/Topiramate 3.75 mg/23 mg)
Days 15-56: VI-0521 (Phentermine/Topiramate 7.5 mg/46 mg)</description>
          </group>
          <group group_id="O3">
            <title>VI-0521 Top Dose</title>
            <description>Days 1-14: VI-0521 (Phentermine/Topiramate 3.75 mg/23 mg)
Days 15-28: VI-0521 (Phentermine/Topiramate 7.5 mg/46 mg)
Days 29-42: VI-0521 (Phentermine/Topiramate 11.25 mg/69 mg)
Days 43-56: VI-0521 (Phentermine/Topiramate 15 mg/92 mg)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Blood Pressure</title>
          <description>Mean change in blood pressure from baseline to Day 56</description>
          <population>The number of subjects with values at both time points (Baseline and Day 56)</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mean change in systolic BP</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.0" spread="12.42"/>
                    <measurement group_id="O2" value="-3.3" spread="10.24"/>
                    <measurement group_id="O3" value="-3.8" spread="9.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean change in diastolic BP</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.2" spread="7.53"/>
                    <measurement group_id="O2" value="3.5" spread="8.11"/>
                    <measurement group_id="O3" value="2.1" spread="6.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in OGTT of Fasting and 2-hour Glucose</title>
        <description>Mean changes in glycemic parameters (OGTT of fasting and 2-hour glucose) from baseline to Day 56</description>
        <time_frame>56 days</time_frame>
        <population>The number of subjects with values at both time points (Baseline and Day 56)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Days 1-56: Placebo</description>
          </group>
          <group group_id="O2">
            <title>VI-0521 Mid Dose</title>
            <description>Days 1-14: VI-0521 (Phentermine/Topiramate 3.75 mg/23 mg)
Days 15-56: VI-0521 (Phentermine/Topiramate 7.5 mg/46 mg)</description>
          </group>
          <group group_id="O3">
            <title>VI-0521 Top Dose</title>
            <description>Days 1-14: VI-0521 (Phentermine/Topiramate 3.75 mg/23 mg)
Days 15-28: VI-0521 (Phentermine/Topiramate 7.5 mg/46 mg)
Days 29-42: VI-0521 (Phentermine/Topiramate 11.25 mg/69 mg)
Days 43-56: VI-0521 (Phentermine/Topiramate 15 mg/92 mg)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in OGTT of Fasting and 2-hour Glucose</title>
          <description>Mean changes in glycemic parameters (OGTT of fasting and 2-hour glucose) from baseline to Day 56</description>
          <population>The number of subjects with values at both time points (Baseline and Day 56)</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mean Change in OGTT of Fasting Serum Glucose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.2" spread="11.66"/>
                    <measurement group_id="O2" value="0.6" spread="4.65"/>
                    <measurement group_id="O3" value="-2.1" spread="9.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean Change in OGTT of 2-Hour Serum Glucose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.2" spread="33.23"/>
                    <measurement group_id="O2" value="-3.9" spread="31.96"/>
                    <measurement group_id="O3" value="-9.3" spread="16.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean Change in OGTT of Fasting Serum Insulin</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.28" spread="25.463"/>
                    <measurement group_id="O2" value="-10.92" spread="31.474"/>
                    <measurement group_id="O3" value="-8.03" spread="6.500"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean Change in OGTT of 2-Hour Serum Insulin</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.45" spread="123.842"/>
                    <measurement group_id="O2" value="-54.13" spread="176.897"/>
                    <measurement group_id="O3" value="-92.99" spread="104.468"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Lipid Parameters</title>
        <description>Mean percent changes in lipid parameters, including total cholesterol, LDL-C, HDL-C and triglycerides (TG) from baseline to Day 56</description>
        <time_frame>56 days</time_frame>
        <population>The number of subjects with values at both time points (Baseline and Day 56)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Days 1-56: Placebo</description>
          </group>
          <group group_id="O2">
            <title>VI-0521 Mid Dose</title>
            <description>Days 1-14: VI-0521 (Phentermine/Topiramate 3.75 mg/23 mg)
Days 15-56: VI-0521 (Phentermine/Topiramate 7.5 mg/46 mg)</description>
          </group>
          <group group_id="O3">
            <title>VI-0521 Top Dose</title>
            <description>Days 1-14: VI-0521 (Phentermine/Topiramate 3.75 mg/23 mg)
Days 15-28: VI-0521 (Phentermine/Topiramate 7.5 mg/46 mg)
Days 29-42: VI-0521 (Phentermine/Topiramate 11.25 mg/69 mg)
Days 43-56: VI-0521 (Phentermine/Topiramate 15 mg/92 mg)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Lipid Parameters</title>
          <description>Mean percent changes in lipid parameters, including total cholesterol, LDL-C, HDL-C and triglycerides (TG) from baseline to Day 56</description>
          <population>The number of subjects with values at both time points (Baseline and Day 56)</population>
          <units>Percent Change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mean Percent Change in TC</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.26" spread="9.154"/>
                    <measurement group_id="O2" value="-6.10" spread="10.857"/>
                    <measurement group_id="O3" value="-1.73" spread="14.103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean Percent Change in LDL-C</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.89" spread="16.532"/>
                    <measurement group_id="O2" value="-4.42" spread="13.567"/>
                    <measurement group_id="O3" value="8.99" spread="26.718"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean Percent Change in HDL-C</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.16" spread="20.539"/>
                    <measurement group_id="O2" value="-6.62" spread="9.887"/>
                    <measurement group_id="O3" value="-12.55" spread="14.248"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean Percent Change in TG</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.54" spread="42.040"/>
                    <measurement group_id="O2" value="0.05" spread="58.326"/>
                    <measurement group_id="O3" value="-8.05" spread="47.167"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Visual Analog Scale (VAS) Hunger Scores</title>
        <description>Mean change in visual analog scale (VAS) hunger scores from baseline to Day 56. VAS hunger score is measured using a 10.0 cm horizontal line. The left end of this line is defined by word descriptors &quot;not at all hungry” and corresponds to a VAS hunger score of 0.0. The right end of this line is defined by word descriptors &quot;extremely hungry all the time” and corresponds to a VAS hunger score of 10.0. Subjects were asked &quot;Please mark with a perpendicular line on the scale how hungry you were overall during the past week:&quot; to best describes their overall level of hunger during the past week. Research staff measure the distance between the &quot;0.0 = not at all hungry&quot; anchor and the mark made by the subject (length to the nearest tenth of a centimeter) to score the measure.</description>
        <time_frame>56 days</time_frame>
        <population>The number of subjects with values at both time points (Baseline and Day 56)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Days 1-56: Placebo</description>
          </group>
          <group group_id="O2">
            <title>VI-0521 Mid Dose</title>
            <description>Days 1-14: VI-0521 (Phentermine/Topiramate 3.75 mg/23 mg)
Days 15-56: VI-0521 (Phentermine/Topiramate 7.5 mg/46 mg)</description>
          </group>
          <group group_id="O3">
            <title>VI-0521 Top Dose</title>
            <description>Days 1-14: VI-0521 (Phentermine/Topiramate 3.75 mg/23 mg)
Days 15-28: VI-0521 (Phentermine/Topiramate 7.5 mg/46 mg)
Days 29-42: VI-0521 (Phentermine/Topiramate 11.25 mg/69 mg)
Days 43-56: VI-0521 (Phentermine/Topiramate 15 mg/92 mg)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Visual Analog Scale (VAS) Hunger Scores</title>
          <description>Mean change in visual analog scale (VAS) hunger scores from baseline to Day 56. VAS hunger score is measured using a 10.0 cm horizontal line. The left end of this line is defined by word descriptors &quot;not at all hungry” and corresponds to a VAS hunger score of 0.0. The right end of this line is defined by word descriptors &quot;extremely hungry all the time” and corresponds to a VAS hunger score of 10.0. Subjects were asked &quot;Please mark with a perpendicular line on the scale how hungry you were overall during the past week:&quot; to best describes their overall level of hunger during the past week. Research staff measure the distance between the &quot;0.0 = not at all hungry&quot; anchor and the mark made by the subject (length to the nearest tenth of a centimeter) to score the measure.</description>
          <population>The number of subjects with values at both time points (Baseline and Day 56)</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.48" spread="1.975"/>
                    <measurement group_id="O2" value="-1.26" spread="2.030"/>
                    <measurement group_id="O3" value="-3.28" spread="2.314"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Visual Analog Scale (VAS) Satiety Scores</title>
        <description>Mean change in visual analog scale (VAS) satiety scores from baseline to Day 56. VAS satiety score is measured using a 10.0 cm horizontal line. The left end of this line is defined by word descriptors &quot;very satisfied” and corresponds to a VAS satiety score of 0.0. The right end of this line is defined by word descriptors &quot;not all at satisfied” and corresponds to a VAS satiety score of 10.0. Subjects were asked &quot;Please mark with a perpendicular line on the scale how satisfied you were after eating during the past week:&quot; to evaluate how satisfied subjects are after eating during the past week. Research staff measure the distance between the &quot;0.0 = very satisfied&quot; anchor and the mark made by the subject (length to the nearest tenth of a centimeter) to score the measure.</description>
        <time_frame>56 days</time_frame>
        <population>The number of subjects with values at both time points (Baseline and Day 56)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Days 1-56: Placebo</description>
          </group>
          <group group_id="O2">
            <title>VI-0521 Mid Dose</title>
            <description>Days 1-14: VI-0521 (Phentermine/Topiramate 3.75 mg/23 mg)
Days 15-56: VI-0521 (Phentermine/Topiramate 7.5 mg/46 mg)</description>
          </group>
          <group group_id="O3">
            <title>VI-0521 Top Dose</title>
            <description>Days 1-14: VI-0521 (Phentermine/Topiramate 3.75 mg/23 mg)
Days 15-28: VI-0521 (Phentermine/Topiramate 7.5 mg/46 mg)
Days 29-42: VI-0521 (Phentermine/Topiramate 11.25 mg/69 mg)
Days 43-56: VI-0521 (Phentermine/Topiramate 15 mg/92 mg)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Visual Analog Scale (VAS) Satiety Scores</title>
          <description>Mean change in visual analog scale (VAS) satiety scores from baseline to Day 56. VAS satiety score is measured using a 10.0 cm horizontal line. The left end of this line is defined by word descriptors &quot;very satisfied” and corresponds to a VAS satiety score of 0.0. The right end of this line is defined by word descriptors &quot;not all at satisfied” and corresponds to a VAS satiety score of 10.0. Subjects were asked &quot;Please mark with a perpendicular line on the scale how satisfied you were after eating during the past week:&quot; to evaluate how satisfied subjects are after eating during the past week. Research staff measure the distance between the &quot;0.0 = very satisfied&quot; anchor and the mark made by the subject (length to the nearest tenth of a centimeter) to score the measure.</description>
          <population>The number of subjects with values at both time points (Baseline and Day 56)</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.74" spread="2.164"/>
                    <measurement group_id="O2" value="-0.65" spread="1.758"/>
                    <measurement group_id="O3" value="0.18" spread="2.221"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Curve (AUC) of Topiramate</title>
        <description>A Bayesian analysis was performed to derive posterior Bayes individual PK parameters. AUC from time 0 to 24 hours under steady-state.</description>
        <time_frame>On Days 14, 28, 42, and 56</time_frame>
        <population>PK samples were not collected for some patients due to withdrawal, or missed visits, etc. As a result, number analyzed for some visits is less than overall number analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>VI-0521 Mid Dose</title>
            <description>Days 1-14: VI-0521 (Phentermine/Topiramate 3.75 mg/23 mg)
Days 15-56: VI-0521 (Phentermine/Topiramate 7.5 mg/46 mg)</description>
          </group>
          <group group_id="O2">
            <title>VI-0521 Top Dose</title>
            <description>Days 1-14: VI-0521 (Phentermine/Topiramate 3.75 mg/23 mg)
Days 15-28: VI-0521 (Phentermine/Topiramate 7.5 mg/46 mg)
Days 29-42: VI-0521 (Phentermine/Topiramate 11.25 mg/69 mg)
Days 43-56: VI-0521 (Phentermine/Topiramate 15 mg/92 mg)</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve (AUC) of Topiramate</title>
          <description>A Bayesian analysis was performed to derive posterior Bayes individual PK parameters. AUC from time 0 to 24 hours under steady-state.</description>
          <population>PK samples were not collected for some patients due to withdrawal, or missed visits, etc. As a result, number analyzed for some visits is less than overall number analyzed.</population>
          <units>μg•h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 14 (Topiramate)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.5" spread="4.49"/>
                    <measurement group_id="O2" value="19.4" spread="4.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28 (Topiramate)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.0" spread="8.98"/>
                    <measurement group_id="O2" value="38.2" spread="9.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 42 (Topiramate)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.8" spread="8.90"/>
                    <measurement group_id="O2" value="60.1" spread="13.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 56 (Topiramate)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.8" spread="8.90"/>
                    <measurement group_id="O2" value="81.4" spread="17.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Concentration (Cmax) of Topiramate</title>
        <description>A Bayesian analysis was performed to derive posterior Bayes individual PK parameters.</description>
        <time_frame>On Days 14, 28, 42, and 56</time_frame>
        <population>PK samples were not collected for some patients due to withdrawal, or missed visits, etc. As a result, number analyzed for some visits is less than overall number analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>VI-0521 Mid Dose</title>
            <description>Days 1-14: VI-0521 (Phentermine/Topiramate 3.75 mg/23 mg)
Days 15-56: VI-0521 (Phentermine/Topiramate 7.5 mg/46 mg)</description>
          </group>
          <group group_id="O2">
            <title>VI-0521 Top Dose</title>
            <description>Days 1-14: VI-0521 (Phentermine/Topiramate 3.75 mg/23 mg)
Days 15-28: VI-0521 (Phentermine/Topiramate 7.5 mg/46 mg)
Days 29-42: VI-0521 (Phentermine/Topiramate 11.25 mg/69 mg)
Days 43-56: VI-0521 (Phentermine/Topiramate 15 mg/92 mg)</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Concentration (Cmax) of Topiramate</title>
          <description>A Bayesian analysis was performed to derive posterior Bayes individual PK parameters.</description>
          <population>PK samples were not collected for some patients due to withdrawal, or missed visits, etc. As a result, number analyzed for some visits is less than overall number analyzed.</population>
          <units>μg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 14 (Topiramate)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.917" spread="0.226"/>
                    <measurement group_id="O2" value="0.952" spread="0.236"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28 (Topiramate)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.84" spread="0.454"/>
                    <measurement group_id="O2" value="1.88" spread="0.465"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 42 (Topiramate)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.92" spread="0.454"/>
                    <measurement group_id="O2" value="2.90" spread="0.594"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 56 (Topiramate)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.92" spread="0.456"/>
                    <measurement group_id="O2" value="3.93" spread="0.817"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in HOMA-IR</title>
        <description>Mean changes in glycemic parameters (HOMA-IR) from baseline to Day 56</description>
        <time_frame>56 days</time_frame>
        <population>The number of subjects with values at both time points (Baseline and Day 56)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Days 1-56: Placebo</description>
          </group>
          <group group_id="O2">
            <title>VI-0521 Mid Dose</title>
            <description>Days 1-14: VI-0521 (Phentermine/Topiramate 3.75 mg/23 mg)
Days 15-56: VI-0521 (Phentermine/Topiramate 7.5 mg/46 mg)</description>
          </group>
          <group group_id="O3">
            <title>VI-0521 Top Dose</title>
            <description>Days 1-14: VI-0521 (Phentermine/Topiramate 3.75 mg/23 mg)
Days 15-28: VI-0521 (Phentermine/Topiramate 7.5 mg/46 mg)
Days 29-42: VI-0521 (Phentermine/Topiramate 11.25 mg/69 mg)
Days 43-56: VI-0521 (Phentermine/Topiramate 15 mg/92 mg)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in HOMA-IR</title>
          <description>Mean changes in glycemic parameters (HOMA-IR) from baseline to Day 56</description>
          <population>The number of subjects with values at both time points (Baseline and Day 56)</population>
          <units>μIU/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.65" spread="7.298"/>
                    <measurement group_id="O2" value="-2.46" spread="7.513"/>
                    <measurement group_id="O3" value="-1.82" spread="1.444"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Whole Body Insulin Sensitivity Index (WBISI) (Matsuda)</title>
        <description>Mean changes in glycemic parameters [Whole Body Insulin Sensitivity Index (WBISI) (Matsuda)] from baseline to Day 56. The Oral Glucose Tolerance Test (OGTT) were performed at Baseline and Day 56 using 75 g oral glucose load; blood samples were obtained at baseline and at 2 hours post glucose load for evaluation of both glucose and insulin levels. Insulin Sensitivity was measured by obtaining glucose and insulin levels in a fasting state and at 2 hours after administration of oral glucose load. Matsuda index = 10,000/SQRT [glucose concentration (mg/dL) (fasting)*insulin concentration (uIU/mL) (fasting)*glucose concentration (mg/dL) (2 hours after glucose load)*insulin concentration (uIU/mL) (2 hours after glucose load)], with higher numbers indicating better insulin sensitivity.</description>
        <time_frame>56 days</time_frame>
        <population>The number of subjects with values at both time points (Baseline and Day 56)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Days 1-56: Placebo</description>
          </group>
          <group group_id="O2">
            <title>VI-0521 Mid Dose</title>
            <description>Days 1-14: VI-0521 (Phentermine/Topiramate 3.75 mg/23 mg)
Days 15-56: VI-0521 (Phentermine/Topiramate 7.5 mg/46 mg)</description>
          </group>
          <group group_id="O3">
            <title>VI-0521 Top Dose</title>
            <description>Days 1-14: VI-0521 (Phentermine/Topiramate 3.75 mg/23 mg)
Days 15-28: VI-0521 (Phentermine/Topiramate 7.5 mg/46 mg)
Days 29-42: VI-0521 (Phentermine/Topiramate 11.25 mg/69 mg)
Days 43-56: VI-0521 (Phentermine/Topiramate 15 mg/92 mg)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Whole Body Insulin Sensitivity Index (WBISI) (Matsuda)</title>
          <description>Mean changes in glycemic parameters [Whole Body Insulin Sensitivity Index (WBISI) (Matsuda)] from baseline to Day 56. The Oral Glucose Tolerance Test (OGTT) were performed at Baseline and Day 56 using 75 g oral glucose load; blood samples were obtained at baseline and at 2 hours post glucose load for evaluation of both glucose and insulin levels. Insulin Sensitivity was measured by obtaining glucose and insulin levels in a fasting state and at 2 hours after administration of oral glucose load. Matsuda index = 10,000/SQRT [glucose concentration (mg/dL) (fasting)*insulin concentration (uIU/mL) (fasting)*glucose concentration (mg/dL) (2 hours after glucose load)*insulin concentration (uIU/mL) (2 hours after glucose load)], with higher numbers indicating better insulin sensitivity.</description>
          <population>The number of subjects with values at both time points (Baseline and Day 56)</population>
          <units>Index</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.19" spread="1.758"/>
                    <measurement group_id="O2" value="0.55" spread="1.226"/>
                    <measurement group_id="O3" value="2.13" spread="2.921"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Placebo: Placebo, po once daily</description>
        </group>
        <group group_id="E2">
          <title>VI-0521 Mid Dose</title>
          <description>VI-0521 Mid Dose: phentermine 7.5 mg and topiramate 46 mg, po once daily</description>
        </group>
        <group group_id="E3">
          <title>VI-0521 Top Dose</title>
          <description>VI-0521 Top Dose: phentermine 15 mg and topiramate 92 mg, po once daily</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle Spasms</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Crohn's disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Urine analysis abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Urine osmolarity increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Poor quality sleep</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Depressed mood</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Skin hyperpigmentation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The PI may publish the result of the study 12 months or longer after termination of the study. The PI will provide the sponsor a copy of any proposed publication at least 30 days prior to submission for publication</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Sr. Director, Clinical Research</name_or_title>
      <organization>VIVUS</organization>
      <phone>650-934-5200</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

